HealthCare Global Enterprises Limited
HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services comprising patient care, psychological support, nutrition and dietetics, multidisciplinary rehabilitation, and genetic counselling. It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology, CAR T cell, translational and nuclear medicine, oncodermatology, anaesthesiology, paediatric and gynaecologic oncology, orthopaedic oncology, uro-oncology, infectious diseases, gastrointestinal and thoracic oncology, breast surgical oncology, clinical pharmacology, and pain and palliative services. In addition, the company operates multi-specialty hospitals under the HCG brand that offers inpatient and outpatient treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care. Further, it provides oncology diagnostics services, including biomarker and translational research, and clinical research services under the Triesta Sciences brand; and fertility treatment services, including reproductive medicine, assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockRule-based from financial data. Not advice.
Historically, Apr has averaged the highest return (+5.9%); Dec the lowest (-4.2%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -10.7%Negative MonthJan 2026: -10.67% | -3.3%Negative MonthFeb 2026: -3.31% | -8.3%Negative MonthMar 2026: -8.30% | +9.1%Positive MonthApr 2026: +9.12% | +11.2%Positive MonthMay 2026: +11.17% | -0.8%Neutral MonthJun 2026: -0.83% | +7.5%*Positive MonthJul 2026: +7.55% | β | β | β | β | β |
| 2025 | +4.6%Positive MonthJan 2025: +4.62% | -1.7%Neutral MonthFeb 2025: -1.67% | +6.9%Positive MonthMar 2025: +6.86% | +4.6%Positive MonthApr 2025: +4.57% | -3.6%Negative MonthMay 2025: -3.60% | +2.1%Positive MonthJun 2025: +2.12% | +12.2%Positive MonthJul 2025: +12.22% | +8.2%Positive MonthAug 2025: +8.20% | -3.8%Negative MonthSep 2025: -3.77% | +15.7%Positive MonthOct 2025: +15.65% | -2.9%Negative MonthNov 2025: -2.94% | -8.8%Negative MonthDec 2025: -8.82% |
| 2024 | +1.5%Neutral MonthJan 2024: +1.50% | -2.4%Negative MonthFeb 2024: -2.37% | -6.7%Negative MonthMar 2024: -6.66% | +8.3%Positive MonthApr 2024: +8.28% | -1.5%Neutral MonthMay 2024: -1.49% | +5.3%Positive MonthJun 2024: +5.35% | -6.8%Negative MonthJul 2024: -6.81% | +9.0%Positive MonthAug 2024: +8.98% | +8.4%Positive MonthSep 2024: +8.36% | +7.4%Positive MonthOct 2024: +7.45% | +11.9%Positive MonthNov 2024: +11.93% | -2.7%Negative MonthDec 2024: -2.68% |
| 2023 | -1.0%Neutral MonthJan 2023: -0.96% | -1.6%Neutral MonthFeb 2023: -1.58% | -6.3%Negative MonthMar 2023: -6.30% | +2.2%Positive MonthApr 2023: +2.15% | +17.4%Positive MonthMay 2023: +17.37% | +1.2%Neutral MonthJun 2023: +1.17% | +1.5%Neutral MonthJul 2023: +1.54% | +8.1%Positive MonthAug 2023: +8.10% | +2.3%Positive MonthSep 2023: +2.33% | +3.6%Positive MonthOct 2023: +3.59% | -0.1%Neutral MonthNov 2023: -0.12% | -1.3%Neutral MonthDec 2023: -1.26% |
| 2022 | +3.6%Positive MonthJan 2022: +3.60% | -7.8%Negative MonthFeb 2022: -7.79% | +18.2%Positive MonthMar 2022: +18.20% | +5.2%Positive MonthApr 2022: +5.17% | -0.8%Neutral MonthMay 2022: -0.85% | -1.2%Neutral MonthJun 2022: -1.23% | -3.1%Negative MonthJul 2022: -3.13% | +1.5%Neutral MonthAug 2022: +1.50% | +4.9%Positive MonthSep 2022: +4.94% | +0.3%Neutral MonthOct 2022: +0.26% | +2.8%Positive MonthNov 2022: +2.83% | -2.8%Negative MonthDec 2022: -2.76% |
| 2021 | β | β | β | β | β | +19.7%Positive MonthJun 2021: +19.73% | +13.5%Positive MonthJul 2021: +13.46% | -5.4%Negative MonthAug 2021: -5.36% | +2.7%Positive MonthSep 2021: +2.69% | -8.9%Negative MonthOct 2021: -8.88% | +12.7%Positive MonthNov 2021: +12.69% | -5.6%Negative MonthDec 2021: -5.57% |
| AvgΒ±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position β all Januaries together, all Februaries together, and so on β to show whether a given month has leaned positive or negative historically. βSimpleβ counts each month as +1 or β1. βWeightedβ gives larger moves more influence: +2 above +10%, β2 below β10%. With only 6 years of history for this asset, each monthβs score reflects a small number of observations β read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the assetβs full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each dayβs closing price by the price on January 1st of that year (or the assetβs first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in βAverage fromβ, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ1.28 K Cr | β | βΉ4.00 Cr | β | β | 0.3% | 9.1% | -87.9% |
| Mar 2024 | βΉ1.17 K Cr | β | βΉ33.00 Cr | β | β | 2.8% | 16.4% | -17.5% |
| Mar 2023 | βΉ1.01 K Cr | β | βΉ40.00 Cr | β | β | 3.5% | 18.4% | 5.3% |
| Mar 2022 | βΉ850.00 Cr | β | βΉ38.00 Cr | β | β | 3.5% | 39.6% | -119.8% |
| Mar 2021 | βΉ609.00 Cr | β | βΉ-192.00 | β | β | -20.8% | -11.5% | 262.3% |
| Mar 2020 | βΉ688.00 Cr | β | βΉ-53.00 | β | β | -8.6% | 7.5% | -857.1% |
| Mar 2019 | βΉ640.00 Cr | β | βΉ7.00 Cr | β | β | 1.1% | 9.2% | -72.0% |
| Mar 2018 | βΉ586.00 Cr | β | βΉ25.00 Cr | β | β | 3.9% | 7.5% | 31.6% |
| Mar 2017 | βΉ545.00 Cr | β | βΉ19.00 Cr | β | β | 3.5% | 15.7% | -480.0% |
| Mar 2016 | βΉ471.00 Cr | β | βΉ-5.00 | β | β | -1.0% | 12.1% | 150.0% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Net Sales | 349 | 420 | 471 | 545 | 586 | 640 | 688 | 609 | 850 | 1,006 | 1,171 | 1,277 | 1,310 |
| Total Expenses | 336 | 364 | 407 | 462 | 498 | 546 | 573 | 535 | 703 | 824 | 970 | 1,065 | 1,096 |
| EBIT / Operating Profit | 13 | 56 | 64 | 83 | 88 | 94 | 116 | 74 | 147 | 181 | 201 | 211 | 213 |
| OPM % | 4% | 13% | 14% | 15% | 15% | 15% | 17% | 12% | 17% | 18% | 17% | 17% | 16% |
| Other Income | 3 | 0 | -1 | 7 | 19 | 13 | -19 | -129 | 65 | 7 | 0 | 4 | -8 |
| Finance Costs | 28 | 32 | 34 | 16 | 27 | 48 | 83 | 63 | 43 | 41 | 50 | 84 | 89 |
| Depreciation & Amortisation | 28 | 33 | 37 | 44 | 44 | 47 | 79 | 87 | 88 | 89 | 97 | 111 | 115 |
| Profit Before Tax | -40 | -8 | -9 | 29 | 37 | 13 | -65 | -205 | 81 | 58 | 54 | 20 | 0 |
| Tax % | -1% | -69% | -45% | 34% | 32% | 42% | -19% | -7% | 53% | 30% | 39% | 82% | - |
| Net Profit / PAT | -40 | -2 | -5 | 19 | 25 | 7 | -53 | -192 | 38 | 40 | 33 | 4 | -13 |
| EPS (βΉ) | -5.79 | -0.34 | -0.56 | 2.27 | 2.86 | 0.82 | -6.01 | -15.28 | 2.75 | 2.89 | 2.35 | 0.25 | -0.94 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| HealthCare Global Enterprises Limitedthis co. | βΉ9.41 K Cr | βΉ1.28 K Cr | 513.00 | 7.95 | 49.86 | 9.1% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |
